TB-500 (Thymosin Beta-4 Fragment)
PeptideThe substantial discrepancy arises from the near-complete absence of medical evidence for TB-500 in humans [s1, s13], while community reports describe positive experiences with injury healing [c1, c2]. Placebo effects, selection bias in forums, and the absence of control conditions account for the difference.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
TB-500 is a synthetic heptapeptide with zero published human RCTs — every regenerative claim rests on animal data, in vitro studies, and anecdotal community reports. Around 60% of users report subjective improvements in chronic tendon and muscle injuries, but ~40% see no effect; product quality from unregulated sources is a serious and repeatedly flagged concern. The risk profile is non-trivial: contamination risks from unvetted peptide suppliers, absent long-term safety data, and a WADA ban (S2) make this a substance to consider only after exhausting conventional therapies and with a clear-eyed understanding of the unknowns. It is contraindicated in anyone with a known or suspected malignancy.
Description
Synthetic heptapeptide (Ac-LKKTETQ) derived from the active fragment of endogenous Thymosin Beta-4. Not approved for human use; investigated in animal and early human studies for tissue regenerat...
TB-500 is a synthetic heptapeptide (N-acetylated LKKTETQ) corresponding to the active region of amino acids 17–23 of the endogenous protein Thymosin Beta-4 (Tβ4) [s1, s6]. Tβ4 itself is a 43-amino acid protein present in virtually all tissues, playing a central role in cell migration, actin regulation, and tissue repair [s5, s7]. TB-500 binds to monomeric G-actin, thereby regulating actin polymerization, which promotes cell migration of fibroblasts, keratinocytes, and endothelial cells [s5, s8]. Preclinical data demonstrate effects on muscle, tendon, cardiac, and nerve tissue in animal models [s9, s10]. Clinical evidence for TB-500 itself (as a heptapeptide) in humans is largely absent; most human studies were conducted with full-length Tβ4, particularly for ophthalmological indications (dry eye, neurotrophic keratopathy) and chronic wounds [s11, s12]. A Phase I study with intravenous Tβ4 in 40 healthy adults found no dose-limiting toxicities up to 1,260 mg/day over 14 days [s13]. A Phase II study with eye drops demonstrated safety and clinical improvement in severe dry eye [s11]. For sports medicine and biohacking-related applications (muscle and tendon regeneration) in humans, no controlled human studies exist. The transferability of animal model findings to humans has not been established [s1, s9]. TB-500 was originally used in veterinary medicine for racehorses and was subsequently adopted by the biohacking community [s14].
Legal Status (DE)
TB-500 and Thymosin β4 are listed on the WADA Prohibited List under category S2 (peptide hormones, growth factors, related substances and mimetics) and have been prohibited since at least 2010. The S2 classification has been confirmed by multiple sources for 2025/2026. An additional S0 classification (non-approved substances) is likely for TB-500; however, this could not be directly verified via the official WADA website (wada-ama.org) in this review. Status: verified May 2026; source: [s3, s32-ref].
Mechanism of Action
The primary mechanism of action of TB-500 is based on binding to monomeric G-actin (binding constant ~0.5 μM) in a 1:1 ratio, inhibiting spontaneous polymerization into F-actin [s5, s8]. This regulation of the actin cytoskeleton enables increased cell motility and migration, particularly of fibroblasts, keratinocytes, and endothelial cells to sites of injury [s5, s8]. Additional described mechanisms based on Tβ4 data: 1. ILK activation (integrin-linked kinase): Tβ4 activates ILK, thereby promoting cardiomyocyte migration and survival [s15]. 2. NF-κB modulation: Anti-inflammatory effects through attenuation of the NF-κB signaling pathway [s9]. 3. Angiogenesis: Promotion of endothelial cell migration and VEGF upregulation support neovascularization [s9, s16]. 4. Collagen synthesis and fibroblast migration: Relevance for tendon, ligament, and skin regeneration [s10]. 5. Neuroprotective effects: In animal models, Tβ4 modulates inflammatory processes in the CNS and promotes neurovascular remodeling [s17, s18]. Important note: The majority of these mechanisms have been described for full-length Tβ4. Whether the heptapeptide TB-500 activates all of these pathways equally in the human organism has not been established by controlled human studies [s1, s11].
Dosing
Verletzungsregeneration (Loading-Phase, anekdotisch)
- Dose
- 2.0–2.5 mg
- Frequency
- 2× pro Woche für 4–6 Wochen
- Route
- injektion-subkutan
- Duration
- 4–6 Wochen
- Timing
- Injection site near the injury or systemically
- With food
- optional
Erhaltungsphase (anekdotisch)
- Dose
- 2.0–2.5 mg
- Frequency
- 1× pro Woche
- Route
- injektion-subkutan
- Duration
- fortlaufend nach Bedarf
- With food
- optional
No officially validated upper limits for humans are available. In the Phase I study with full-length Tβ4, doses up to 1,260 mg/day i.v. were administered over 14 days without dose-limiting toxicity — however, these data are not transferable to TB-500 (heptapeptide) [s13]. All referenced protocols are based exclusively on anecdotal community reports without clinical validation.
TB-500 is not approved for human use [s1, s2]. All dosing information is derived from uncontrolled self-reports within the biohacking community [c1, c2]. Products from unregulated sources may contain endotoxins, solvent residues, heavy metals, microbial contaminants, or incorrectly declared peptide sequences [s19].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Injektionsstellenreaktionen (Rötung, Schwellung, Schmerz) Typical reaction to subcutaneous peptide injections. Frequently mentioned in community reports [c1]. Risk increased by non-sterile conditions during self-injection [s19]. | gelegentlich | leicht |
| Vorübergehende Lethargie oder mentale Benommenheit (erste Woche) Reported anecdotally during the first week of use; mechanism unclear [s20]. | gelegentlich | leicht |
| Kopfschmerzen Mentioned in community reports and informal safety reports [s20]. | gelegentlich | leicht |
| Grippe-ähnliche Symptome (Loading-Phase) Occasionally reported during the initial loading phase; possible immune activation [s20, c1]. | selten | leicht |
| Hypersensitivitätsreaktion / Anaphylaxie With repeated injections of foreign peptides, a hypersensitivity reaction including life-threatening anaphylaxis is theoretically possible [s21]. | theoretisch | schwer |
| Tumorwachstum / onkologisches Risiko Tβ4 is overexpressed in some tumor cells. Its pro-angiogenic properties could theoretically promote existing tumors. Causal human studies are lacking; the risk is considered theoretical but not excluded [s22, s6]. | theoretisch | schwer |
| Kontaminationsrisiko (Endotoxine, Lösungsmittel, mikrobielle Verunreinigungen) As TB-500 is sourced from unregulated suppliers, there is a real risk of product contamination with endotoxins, solvent residues, heavy metals, and microbial agents [s19]. | gelegentlich | moderat |
Contraindications
Tβ4 is overexpressed in various tumor cell lines; angiogenic and pro-proliferative properties may theoretically promote tumor growth and metastasis [s22, s6].
No safety data available for pregnant or breastfeeding women. Proliferative and angiogenic effects pose a theoretical risk to fetal development [s1].
Anaphylactic reactions to injectable peptides have been reported; history of hypersensitivity reactions is a contraindication [s21].
Tβ4 modulates immune processes; its effect on autoimmune diseases has not been established [s17].
TB-500 and Tβ4 have been listed on the WADA prohibited list (S0 and S2) since 2018. Detection results in disqualification [s3, s4].
Interactions
Synergistic
Frequently combined in the biohacking community; both peptides are purported to promote tissue regeneration and angiogenesis. No controlled human studies available for this combination [c3].
KPV and TB-500 are used as a regenerative duo in the biohacking community. Both peptides are purported to exert anti-inflammatory effects and promote tissue healing via complementary pathways.
GHK-Cu and TB-500 both exhibit regenerative properties, particularly in dermatological applications and wound healing. Their combination may produce synergistic effects in skin regeneration.
CJC-1295 and TB-500 are frequently used together to support tissue and muscle regeneration. CJC-1295 elevates GH/IGF-1 levels, while TB-500 locally promotes cell migration and repair.
Ipamorelin is often used as part of a GH stack with CJC-1295 alongside TB-500 for improved recovery and tissue regeneration. This combination is purported to shorten healing time following injuries.
Caution
Angiogenic effects of Tβ4 could theoretically interact with anticoagulants; no clinical data available [s9].
Combined pro-proliferative effects could theoretically increase oncological risk; no human studies available [s22].
Tβ4 modulates immune processes; interactions with immunosuppressants are theoretically possible but have not been investigated [s17].
Community Evidence
Top reported benefits
- Accelerated recovery from tendon and muscle injuries
- Reduction of chronic pain in overuse syndromes
- Improvement following surgery (e.g., tendon repair)
- Combination with BPC-157 as a popular recovery protocol
Top reported issues
- Approx. 40% of users report no noticeable effect
- Quality and purity concerns with unregulated sources
- Injection site reactions
- High costs for multi-week protocols
Community members repeatedly highlight the absence of long-term safety data and unregulated product quality. Experienced users advise use only for chronic, treatment-resistant injuries after exhaustion of conventional therapies. The lack of clinical studies for the heptapeptide TB-500 itself (vs. full-length Tβ4) is cited as a critical issue [c1, c2, c3].
Scientific Sources
- TB-500 - Status, Risks, and Bans in Sport and Military
BSCG (Ban Side Consumer Guard) (2024). BSCG BlogBLink - TB-500 (Thymosin Beta-4) – Promotion of fibroblast migration and collagen synthesis
AminoPharm Editorial (2024). AminoPharmCLink - Phase 2 Randomized Double-Masked Trial of Thymosin Beta-4 Eye Drops for Severe Dry Eye Disease
Sosne G, Siddiqi A, Kurpakus-Wheater M, et al. (2022). Journal of Cellular and Molecular Medicine (referenced via PeptideJournal.org and JeffreyPengMD)ALink - Clinical study of topical Thymosin beta-4 in venous stasis ulcers and pressure sores
Guarnieri G, et al. (2010). ClinicalTrials.gov NCT00832091BLink - Phase I Safety Study of Intravenous Thymosin Beta-4 in Healthy Adults
Goldstein AL, Kleinman HK, Sosne G, et al. (2012). Nature Dermatology / NaturaDermatology referencedALink - TB4 and TB-500 Peptide Therapy – Veterinary Origins and Human Adoption
InnerBody Editorial (2026). InnerBodyCLink - Thymosin beta 4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair
Bock-Marquette A, Saxena M, White MD, et al. (2004). NatureCPMID:15549107DOI - The actin binding site on thymosin beta4 promotes angiogenesis
Philp D, Huff T, Gho YS, et al. (2003). FASEB JournalCLink - Anti-inflammatory potential of thymosin β4 in the central nervous system: implications for progressive neurodegenerative diseases
Santra M, Chopp M, Santra S, et al. (2018). Expert Opinion on Biological Therapy (PubMed)BPMID:30063850 - Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases
Chopp M, Zhang ZG (2015). Expert Opinion on Biological Therapy (PubMed)BPMID:25613458 - The Peptide Gamble: Contamination and Quality Risks of Unregulated BPC-157 and TB-500
OrthoAndWellness Editorial (2024). OrthoAndWellness BlogCLink - Rechtlicher Status TB-500 in Deutschland – Forschungschemikalie
parahealth.de (2026). parahealth.de BlogCLink - TB-500 Side Effects: Safety Profile, Risks & Real Reports
MedsBase Editorial (2024). MedsBaseCLink - What are the adverse effects of TB-500 (Thymosin Beta-4)? – Hypersensitivity and anaphylaxis
DrOracle Editorial (2024). DrOracle.aiCLink - TB-500 Exposed: Cancer Risk and Oncological Concerns
OrthoAndWellness Editorial (2024). OrthoAndWellness BlogCLink - Peptide Nebenwirkungen – TB-500 und Krebsrisiko
Peptide Culture Editorial (2024). Peptide Culture BlogCLink - TB 500 – DocCheck Flexikon
DocCheck Flexikon Editorial (2023). DocCheck FlexikonCLink - Peptid-Hype in Tech-Kreisen – TB-500 und BPC-157
Pharmazeutische Zeitung Editorial (2024). Pharmazeutische ZeitungBLink - Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
Sosne G, Ousler GW (2015). Clinical OphthalmologyCDOI - 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
Sosne G, et al. (2023). Journal of Clinical MedicineCLink - Thymosin beta 4 has a major role in dermal burn wound healing that involves actin cytoskeletal remodelling via heat-shock protein 70
Kim S, Kwon J (2017). Journal of Tissue Engineering and Regenerative MedicineCPMID:25921810DOI - Role of thymosin beta4 in tumor metastasis and angiogenesis
Kim S, Kwon J (2003). Journal of the National Cancer InstituteCLink - The Prohibited List 2026
World Anti-Doping Agency (WADA) (2026). WADAALink - Thymosin Beta 4 Protects Hippocampal Neuronal Cells against PrP (106–126) via Neurotrophic Factor Signaling
Kim S, Choi J, Kwon J (2023). MoleculesCDOI - WADA-Verbotsliste 2018 ins Deutsche übersetzt – Thymosin beta-4 und TB-500 neu aufgenommen
NADA Deutschland (2018). NADAALink - TB-500 Peptide Research: The Science Behind Thymosin Beta-4
BioLongevity Labs (2024). BioLongevity Labs ResearchCLink - Progress on the Function and Application of Thymosin β4
Xing Y, Ye Y, Zuo H, et al. (2021). Frontiers in Endocrinology / PMCBLink - TB-500 (Thymosin Beta-4): Actin Sequestration & Cell Migration Studies
PeptidesSource Editorial (2023). PeptidesSourceCLink - TB-500 (Thymosin Beta-4) | Peptide Biologix – Mechanism of Action
Peptide Biologix Editorial (2024). Peptide BiologixCLink - TB-500 (Thymosin Beta-4): The Complete Research Guide to Recovery and Tissue Repair
Spartan Peptides Editorial (2024). Spartan Peptides BlogCLink
Community Sources
Storage
Unopened
Store at -20 °C; lyophilized powder is stable for 24 months under correct storage conditions.
Opened
After reconstitution with bacteriostatic water, store at 2–8 °C; use within 28 days.
Notes
Light exposure and heat accelerate degradation. Products from unregulated sources may already be contaminated or defective upon receipt, regardless of correct storage by the end user [s19].